Goldman Sachs
ALXN

Goldman Sachs’s Alexion Pharmaceuticals ALXN Stock Holding History

Goldman Sachs’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-781,412
Closed -$144M – 6757
2021
Q2 		$144M Buy
781,412
+119,633
+18% +$20.5M 0.03% 540
2021
Q1 		$101M Sell
661,779
-108,377
-14% -$16.8M 0.03% 643
2020
Q4 		$120M Sell
770,156
-716,030
-48% -$92M 0.03% 527
2020
Q3 		$170M Buy
1,486,186
+191,823
+15% +$20.7M 0.05% 381
2020
Q2 		$145M Sell
1,294,363
-34,096
-3% -$3.62M 0.04% 412
2020
Q1 		$119M Sell
1,328,459
-1,759,846
-57% -$173M 0.04% 451
2019
Q4 		$334M Buy
3,088,305
+583,774
+23% +$62.4M 0.09% 246
2019
Q3 		$245M Buy
2,504,531
+323,720
+15% +$36.5M 0.07% 308
2019
Q2 		$286M Buy
2,180,811
+684,850
+46% +$88.3M 0.08% 239
2019
Q1 		$202M Sell
1,495,961
-151,257
-9% -$18.8M 0.06% 353
2018
Q4 		$160M Sell
1,647,218
-444,048
-21% -$52.5M 0.05% 397
2018
Q3 		$291M Sell
2,091,266
-342,897
-14% -$43M 0.08% 273
2018
Q2 		$302M Sell
2,434,163
-29,083
-1% -$3.4M 0.08% 238
2018
Q1 		$275M Sell
2,463,246
-1,681,190
-41% -$201M 0.07% 304
2017
Q4 		$496M Buy
4,144,436
+686,209
+20% +$83.6M 0.12% 164
2017
Q3 		$485M Sell
3,458,227
-1,343,647
-28% -$183M 0.12% 145
2017
Q2 		$584M Buy
4,801,874
+3,237,464
+207% +$377M 0.15% 107
2017
Q1 		$190M Buy
1,564,410
+434,644
+38% +$56M 0.05% 407
2016
Q4 		$138M Sell
1,129,766
-935,906
-45% -$115M 0.04% 573
2016
Q3 		$253M Buy
2,065,672
+616,476
+43% +$79.4M 0.08% 253
2016
Q2 		$169M Buy
1,449,196
+515,000
+55% +$73.1M 0.06% 410
2016
Q1 		$130M Sell
934,196
-427,874
-31% -$62.8M 0.04% 534
2015
Q4 		$260M Buy
1,362,070
+217,900
+19% +$38.1M 0.08% 253
2015
Q3 		$179M Sell
1,144,170
-274,886
-19% -$50.1M 0.06% 350
2015
Q2 		$257M Buy
1,419,056
+900,791
+174% +$155M 0.08% 264
2015
Q1 		$89.8M Sell
518,265
-44,056
-8% -$7.97M 0.03% 705
2014
Q4 		$104M Sell
562,321
-121,403
-18% -$22.5M 0.03% 660
2014
Q3 		$113M Sell
683,724
-176,008
-20% -$28.9M 0.04% 577
2014
Q2 		$134M Sell
859,732
-226,683
-21% -$35.8M 0.04% 524
2014
Q1 		$165M Buy
1,086,415
+10,433
+1% +$1.66M 0.05% 391
2013
Q4 		$143M Sell
1,075,982
-22,198
-2% -$2.66M 0.05% 462
2013
Q3 		$128M Sell
1,098,180
-209,991
-16% -$23M 0.05% 477
2013
Q2 		$121M Buy
+1,308,171
New +$126M 0.05% 464

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Goldman Sachs's ALXN Position: Q3 2021 in Review

Goldman Sachs sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 781,412 shares — an estimated $144M sold.

Goldman Sachs first reported a position in ALXN in Q2 2013 and held it in 33 quarters. The position peaked at $584M in Q2 2017. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Goldman Sachs reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Goldman Sachs sold 781,412 Alexion Pharmaceuticals shares in Q3 2021, an estimated $144M.
  • Goldman Sachs first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 33 quarters.
  • Goldman Sachs's Alexion Pharmaceuticals position peaked at $584M in Q2 2017.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Goldman Sachs's 13F filing for Q3 2021, filed 10 Nov 2021.